| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.2174/1381612043453027 |
| P698 | PubMed publication ID | 15032698 |
| P50 | author | Stephen M. Husbands | Q42352975 |
| P2093 | author name string | John W Lewis | |
| P433 | issue | 7 | |
| P921 | main subject | opioid | Q427523 |
| P304 | page(s) | 717-732 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Current Pharmaceutical Design | Q5195068 |
| P1476 | title | The orvinols and related opioids--high affinity ligands with diverse efficacy profiles | |
| P478 | volume | 10 |
| Q44329921 | 3D-QSAR studies of orvinol analogs as kappa-opioid agonists |
| Q30570686 | A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine |
| Q28652289 | Anti-nociception mediated by a κ opioid receptor agonist is blocked by a δ receptor agonist |
| Q34423181 | BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice |
| Q24187076 | Buprenorphine for treating cancer pain |
| Q36190545 | Buprenorphine in cancer pain |
| Q34615753 | Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy |
| Q35669185 | C7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors. |
| Q41134315 | Cinnamoyl derivatives of 7alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands |
| Q51529259 | Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. |
| Q42049079 | Effects of buprenorphine in the adrenal, thyroid, and cytokine intra-operative responses in a rat model (Rattus norvegicus): a preliminary study |
| Q62390901 | Functionalization of the 6,14-Bridge of the Orvinols |
| Q36156117 | Functionalization of the 6,14-bridge of the orvinols. Part 3: preparation and pharmacological evaluation of 18- and 19-hydroxyl substituted orvinols |
| Q44343238 | Methyl-orvinol-Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome |
| Q41899831 | Molecular details of the activation of the μ opioid receptor. |
| Q36822435 | Orvinols with mixed kappa/mu opioid receptor agonist activity |
| Q33566172 | Pharmacological mechanisms underlying the antinociceptive and tolerance effects of the 6,14-bridged oripavine compound 030418 |
| Q47128255 | Photoredox Imino Functionalizations of Olefins |
| Q26992051 | Positron emission tomography molecular imaging of dopaminergic system in drug addiction |
| Q36711173 | Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management |
| Q33662388 | Selectively promiscuous opioid ligands: discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity |
| Q35284997 | Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine |
| Q41904743 | Synthesis and opioid receptor binding of indium (III) and [111In]-labeled macrocyclic conjugates of diprenorphine: novel ligands designed for imaging studies of peripheral opioid receptors |
| Q57073139 | Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile |
| Q38669787 | The effectiveness of buprenorphine for treating cancer pain: an abridged Cochrane review |
| Q90548695 | Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option |
| Q37855806 | Utilizing nature as a source of new probes for opioid pharmacology |
Search more.